The invention relates to the chemistry of organic compounds, pharmacology and medicine and concerns therapy for obesity, psoriasis, Crohn's disease, colitis, irritable bowel syndrome, diarrhea, nausea and vomiting, as well as a number of other diseases associated with the activity of cathepsin S, cannabinoid receptors type 1, tachykinin receptors type 1 and 2, prokineticin receptors type 1 and 2, bradykinin receptors type 1, melanocortin receptors MC4R, serotonin receptors 5-HT2B and NB-kB signaling pathway, by using benzyl (2S)-2-[2-(4-hydroxyphenyl)acetamido]-3-phenylpropanoate compound. ##STR00001## The compound and pharmaceutically acceptable adducts, hydrates and solvates thereof are a cathepsin S inhibitor, cannabinoid receptor type 1 agonist, tachykinin receptor type 1 and 2 antagonist, prokineticin receptor type 1 and 2 antagonist, bradykinin receptor type 1 antagonist, melanocortin receptor MC4R antagonist, serotonin receptor 5-HT2B antagonist, and NB-kB signaling pathway inhibitor. The invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of the compound according to the invention.

Use of a compound as shown in formula I in preparation of a medicament for prevention, treatment or amelioration of learning, memory and cognitive impairment of Down's syndrome. The compound as shown in formula I can enhance the learning and memory ability of a Down's mouse, increase the number of synapses in the hippocampus of the Down's mouse, and can restore the damaged phagocytic function of the brain microglia cell of the Down's mouse. Therefore, the compound can be used as a therapeutic medicament to be applied to the symptoms of learning, memory and cognitive impairment of Down's syndrome.

##STR00001##

The present invention relates to pharmaceutical compositions for topical use comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in treating allergic dermatitis, particularly insect bite hypersensitivity, in animals using the compositions of the invention are also described

The present invention relates to pharmaceutical compositions for topical use comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in treating allergic dermatitis, particularly insect bite hypersensitivity, in animals using the compositions of the invention are also described

An oseltamivir formulation and a preparation method of the formulation, the method being simple to operate, having good reproducibility, and being suitable for manufacture. The oseltamivir formulation includes oseltamivir or a salt thereof and a sustained-release material. The formulation may be a single-phase release formulation, a dual-phase release formulation, a three-phase release formulation, or a multi-phase release formulation having more than three phases. The formulation is administered once-daily and can achieve sustained release of at least 24 hours or longer, which can reduce the times of administration and avoid peak-to-valley fluctuations, thereby improving the compliance and safety of patients.

An oseltamivir formulation and a preparation method of the formulation, the method being simple to operate, having good reproducibility, and being suitable for manufacture. The oseltamivir formulation includes oseltamivir or a salt thereof and a sustained-release material. The formulation may be a single-phase release formulation, a dual-phase release formulation, a three-phase release formulation, or a multi-phase release formulation having more than three phases. The formulation is administered once-daily and can achieve sustained release of at least 24 hours or longer, which can reduce the times of administration and avoid peak-to-valley fluctuations, thereby improving the compliance and safety of patients.

The present disclosure provides methods for site-selectively crosslinking payloads to antibodies and other proteins. This can be accomplished using traceless affinity labels designed to label target proteins with bio-orthogonally reactive entities (ORE) using the compositions and methods described herein.

The present disclosure provides methods for site-selectively crosslinking payloads to antibodies and other proteins. This can be accomplished using traceless affinity labels designed to label target proteins with bio-orthogonally reactive entities (ORE) using the compositions and methods described herein.

Sprayable compositions comprising a pyrethroid, a viscosity building agent, an emulsifier or surfactant, and an emollient are provided. The compositions have a viscosity that allows for delivery of the spray from a pressurized container such that the pyrethroid is administered in a consistent amount that uniformly covers the body of a subject. This obviates the need to rub the composition into the skin. In preferred embodiments, the pyrethroid is permethrin; the viscosity building agent is selected from the group consisting of carbomers, xanthan gum, or a combination thereof; the emulsifier or surfactant is selected from the group consisting of glyceryl mononstearate, PEG40 hydrogenated castor oil, cholesterol, steareth-10, steareth-20, and combinations thereof; and the emollient is selected from the group consisting of C12-C15 alkyl benzoates, diisopropyl adipate, silicon oil, mineral oil, or any combination thereof.

Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of a the device.